-
Mashup Score: 0Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol | Future Oncology - 1 day(s) ago
OPTYX is a multi-center, prospective, observational study designed to further understand the actual experience of patients with advanced prostate cancer treated with relugolix (ORGOVYX®), an oral androgen deprivation therapy (ADT), by collecting clinical and patient-reported outcomes from routine care settings. The study aims to enroll 1000 consented patients with advanced prostate cancer from community, academic and government operated clinical practices across the USA. At planned timepoints, real-world data analysis on treatment patterns, adherence and safety as well as health outcomes and health-related quality-of-life (HRQOL) after treatment discontinuation will be published in scientific peer-reviewed journals and presented at relevant conferences. This study will provide real-world data for practitioners and researchers in their understanding of the safety and effectiveness of relugolix. Clinical Trial Registration: NCT05467176 (ClinicalTrials.gov)
Source: www.futuremedicine.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol | Future Oncology - 9 day(s) ago
OPTYX is a multi-center, prospective, observational study designed to further understand the actual experience of patients with advanced prostate cancer treated with relugolix (ORGOVYX®), an oral androgen deprivation therapy (ADT), by collecting clinical and patient-reported outcomes from routine care settings. The study aims to enroll 1000 consented patients with advanced prostate cancer from community, academic and government operated clinical practices across the USA. At planned timepoints, real-world data analysis on treatment patterns, adherence and safety as well as health outcomes and health-related quality-of-life (HRQOL) after treatment discontinuation will be published in scientific peer-reviewed journals and presented at relevant conferences. This study will provide real-world data for practitioners and researchers in their understanding of the safety and effectiveness of relugolix. Clinical Trial Registration: NCT05467176 (ClinicalTrials.gov)
Source: www.futuremedicine.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0A journey through value-based oncology care - 13 day(s) ago
What challenges are associated with value-based oncology care and how can these be overcome?
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Frontiers in brain tumor research and empowering women in STEM - 21 day(s) ago
Discover the strides being made to unravel the complexities of brain tumors in our latest interview with Karen Noble.
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0A journey through value-based oncology care - 22 day(s) ago
What challenges are associated with value-based oncology care and how can these be overcome?
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Championing diversity and inclusion in neuro-oncology - 24 day(s) ago
Explore opportunities for women in neuro-oncology with Dr Macarena Ines De La Fuente who has been the co-chair of the SNO’s Women and Diversity Committee.
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
How can MRI-guided radiation therapy offer in terms of real-time insights into glioblastoma disease progression?
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0A journey through value-based oncology care - 28 day(s) ago
What challenges are associated with value-based oncology care and how can these be overcome?
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions | Future Oncology - 29 day(s) ago
Neuregulin 1 (NRG1) fusions are oncogenic drivers that have been detected in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. NRG1 fusions are rare, occurring in less than 1% of solid tumors. Patients with NRG1 fusion positive (NRG1+) cancer have limited therapeutic options. Zenocutuzumab is a novel, bispecific IgG1 antibody that targets both HER2 and HER3 proteins and inhibits NRG1 binding through a ‘Dock & Block®’ mechanism of action. Here, we describe the rationale and design of the phase II component of the eNRGy trial, part of the overall, open-label phase I/II, multicenter trial exploring the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of zenocutuzumab in patients with NRG1+ NSCLC, PDAC or other solid tumors.
Source: www.futuremedicine.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0The Phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions - 1 month(s) ago
eNRGy is a clinical trial of zenocutuzumab for cancer caused by NRG1 gene fusions. Find out more in our latest journal feature here.
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet
OPTYX study aims to generate evidence on ORGOVYX's safety and effectiveness in prostate cancer patients in routine care, including treatment course and post-treatment clinical outcomes. >>> https://t.co/6aQGJkVcb3 https://t.co/7k2bfdHVFh